Appendage Management was AtriCure’s largest product and service line in fiscal 2025, bringing in $220.18M of $536.98M (41%).
| Product and Service | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Appendage Management | $132.38M | $160.02M | $185.66M | $220.18M | ||||||||||
| Open Ablation | $112.93M | $136.77M | $158.34M | $184.89M | ||||||||||
| Open-Heart Ablation | — | — | — | — | ||||||||||
| Open-Heart | — | — | — | — | ||||||||||
| Pain Management | $40.53M | $51.21M | $67.47M | $89.62M | ||||||||||
| Minimally Invasive Ablation | $44.54M | $51.25M | $53.84M | $39.85M | ||||||||||
| Minimally Invasive | — | — | — | — | ||||||||||
| Atriclip Devices | — | — | — | — | ||||||||||
| Atriclip | — | — | — | — | ||||||||||
| Valve Tools | — | — | — | — | ||||||||||
| Shipping & Handling | $1.50M | $1.86M | $2.42M | $2.45M | ||||||||||
| Total | $331.88M | $401.11M | $467.73M | $536.98M |
AtriCure brought in $536.98M from its five product and service lines in fiscal 2025, the year ended December 31, 2025. That was up 14.8% from $467.73M in fiscal 2024. Appendage Management was the largest at $220.18M (41.0%), ahead of Open Ablation at $184.89M (34.4%) and Pain Management at $89.62M (16.7%). The other two lines brought in $42.30M combined.
Compared with fiscal 2024, Pain Management grew fastest, up 32.8% to $89.62M, while Minimally Invasive Ablation fell the most, down 26.0% to $39.85M. From fiscal 2022 to 2025, combined revenue from these lines grew from $331.88M to $536.98M, a compound annual growth rate of 17.4%. Appendage Management's share of the total rose from 39.9% to 41.0%.
United States was AtriCure’s largest region in fiscal 2025, bringing in $435.37M of $534.53M (81%).
| Geography | FY 2010 | FY 2011 | FY 2012 | FY 2013 | FY 2014 | FY 2015 | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $277.20M | $333.54M | $382.82M | $435.37M | ||||||||||||
| Openheart | — | — | — | — | ||||||||||||
| Europe | $30.43M | $38.47M | $49.87M | $61.49M | ||||||||||||
| Asia-Pacific | $20.73M | $24.53M | $27.38M | $30.72M | ||||||||||||
| Minimally Invasive | — | — | — | — | ||||||||||||
| Segment Geographical Groups Of Countries Group One | — | — | — | — | ||||||||||||
| Asia | — | — | — | — | ||||||||||||
| Articlip | — | — | — | — | ||||||||||||
| Other International | $2.02M | $2.71M | $5.24M | $6.94M | ||||||||||||
| Total | $330.38M | $399.25M | $465.31M | $534.53M |
AtriCure brought in $534.53M from its four regions in fiscal 2025, the year ended December 31, 2025. That was up 14.9% from $465.31M in fiscal 2024. United States was the largest at $435.37M (81.4%), ahead of Europe at $61.49M (11.5%) and Asia-Pacific at $30.72M (5.7%). The remaining region, Other International, brought in $6.94M.
Compared with fiscal 2024, Europe grew fastest, up 23.3% to $61.49M. Every region above 2% of revenue grew. From fiscal 2022 to 2025, combined revenue from these regions grew from $330.38M to $534.53M, a compound annual growth rate of 17.4%. United States' share of the total fell from 83.9% to 81.4%.
Domestic was AtriCure’s largest revenue line in fiscal 2011, bringing in $48.93M of $64.40M (76%).
| Income Tax Authority | FY 2011 |
|---|---|
| Domestic | $48.93M |
| International | $15.47M |
| Total | $64.40M |
AtriCure brought in $64.40M from its two revenue lines in fiscal 2011, the year ended December 31, 2011. Domestic was the largest at $48.93M (76.0%), ahead of International at $15.47M (24.0%).
AtriCure (ATRC) reports its revenue by product and service, by geography and by income tax authority. In fiscal 2025, Appendage Management was its largest product and service line, bringing in $220.18M (41.0% of the total), followed by Open Ablation at $184.89M (34.4%).
Appendage Management was AtriCure's largest product and service line in fiscal 2025, bringing in $220.18M, or 41.0% of the $536.98M total across its five product and service lines.
United States was AtriCure's largest region in fiscal 2025, bringing in $435.37M, or 81.4% of the $534.53M total across its four regions.
Domestic was AtriCure's largest revenue line in fiscal 2011, bringing in $48.93M, or 76.0% of the $64.40M total across its two revenue lines.
Among AtriCure's product and service lines that make up at least 2% of revenue, Pain Management grew fastest in fiscal 2025, up 32.8% from $67.47M to $89.62M.
Every figure comes from AtriCure's annual financial filings, as reported. Each line keeps the name AtriCure gives it, and years follow its fiscal calendar.
AtriCure's revenue by product and service goes back to fiscal 2012, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.